Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation

实验性的：Cytokine-induced Killer Cells

The first cohort =1X10 7 cf expanded cells/kg. The second cohort = 5x10 7 expanded cells/kg. The second cohort = 1X10 8 expanded cells/kg.

药品：Cytokine Induced Killer Cells

CIK cell dose escalation will be performed in cohorts of three patients per group. The initial dose utilized will be 1x107 expanded cells/kg. Previously, unmanipulated donor lymphocytes administered at this dose did not result in significant GVHD 7. The expansion of the CIK cell population is expected to diminish the T cell subsets responsible for GVHD further reducing the risk of GVHD to recipients. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD in the recipients

To determine the feasibility of expanding allogeneic cytokine induced killer cells suitable for clinical application using a continuous perfusion culture system.

To determine the infusional toxicity of ex vivo expanded allogeneic CIK cells in patients with recurrent or refractory disease following allogeneic hematopoietic cell transplantation.

To determine the incidence of Graft-versus-Host Disease (GVHD) following infusion of allogeneic CIK cells.

To determine the maximum tolerated dose (MTD) of expanded CIK cells for infusion.

o determine the incidence of disease response following treatment with allogeneic CIK cells.

To assess donor-specific chimerism before and after treatment with allogeneic CIK cells.

To optimize the ex vivo expansion of CIK cells using a continuous perfusion culture system.